The Jiang Group - Personalised Medicine and Autoimmunity

The Jiang Group utilises personalised medicine to understand the unique causes of disease in individual patients and their families. Conventional management of autoimmune disease assumes the causes of disease are similar in each individual and as a result many autoimmune treatments are variably effective despite significant side effect profiles. Our laboratory identifies disease-causing genetic variants and investigates how these variants impair immune function leading to autoimmunity and kidney disease. We leveraging this understanding of an individual’s genetic, molecular and cellular mechanisms driving these illnesses we can then develop personalised treatments for each individual.

The Personalised Medicine and Autoimmunity laboratory leads a national personalised medicine program for physicians and patients with autoimmune disease. Novel insights into the causes of disease have allowed us to start development of new therapies for treatment of autoimmune disease. Further, we have adapted this approach to understand the causes of endemic kidney and immune disease in Indigenous Australian communities with the aim of improving community health outcomes. We continue to develop new methods of understanding illness including artificial intelligence.

Projects

  • Genetic and phenomic basis of autoimmunity and kidney disease

  • Genetic and molecular basis of kidney and immune disease in Indigenous Australians

  • Development of artificial intelligence in autoimmune kidney disease

We welcome enquiries from potential Honours, PhD and Postdoctoral fellows contact us to discuss research opportunities in these domains. For more information, please contact vicki.athanasopoulos@anu.edu.au or simon.jiang@anu.edu.au

Jiang SH, Mercan S, Papa I, Moldovan M, Walters GD, Koina M, Fadia M, Stanley M, Lea-Henry TN, Cook A, Ellyard JI, McMorran B, Sundaram M, Thomson R, Canete PF, Hoy W, Hutton H, Srivastava M, McKeon K, Athanasopoulos V, Field F, Mathews J, Cho E, Andrews TD, Kitching AR, Cook MC, Alarcon Riquelme M, Bahlo M, Vinuesa CG Deletions in VANGL1 are a novel risk factor for antibody mediated kidney disease. Cell Reports Medicine December 21, 2021

Jiang SH, Athanasopoulos V, Ellyard JI, Chuah A, Cappello J, Cook A, Prabhu SB, Cardenas J, Gu J, Stanley M, Roco JA, Papa I, Yabas M, Walters GD, Burgio G, McKeon K, Byers JM, Burrin C, Enders A, Miosge LA, Canete PF, Jelusic M, Tasic V, Lungu AC, Alexander SI, Kitching AR, Fulcher DA, Shen N, Arsov T, Gatenby PA, Babon JJ, Mallon DF, de Lucas Collantes C, Stone EA, Wu P, Field MA, Andrews TD, Cho E, Pascual V, Cook MC, Vinuesa CG. Functional rare and low frequency variants in BLK and BANK1 contribute to human lupus. Nat Comm. 2019 May 17;10(1):2201.

Lea-Henry TN, Chuah A, Stanley M, Athanasopoulos V, Starkey M, Christiadi D, Kitching AR; Cook MC, Andrews TD, Vinuesa CG, Walters GD, Jiang SH Increased burden of rare variants in genes of the endosomal Toll-like receptor pathway in patients with systemic lupus erythematosus Lupus July 16, 2021.

He Y, Gallman A, Xie C, Shen Q, Ma J, Wolfreys F, Sandy M, Arsov T, Wu X, Qin Y, Zhang P, Jiang SH, Stanley M, Wu P, Tan J, Ding H, Xue H, Chen W, Xu J, A. Criswell, Nititham J, Adamski M, Cook MC, Cao L, Shen N, Cyster J, and Vinuesa CG P2RY8 variants in lupus patients uncover a role for the receptor in immunological tolerance J Ex Med 2022 219 (1):e20211004

Puri P., Yang Y, Jiang SH, Mackay F, Yu D Understanding SLE heterogeneity in the age of big data and artificial intelligenceRheumatology and Autoimmunity October 11, 2021

Easteal S, Arkell RM, Balboa RF, Bellingham SA, Brown, AD, Calma T, Cook MC, Davis M, Dawkins HJS, Dinger ME, Dobbie MS, Farlow, Ashley, Gwynne KG, Hermes A, Hoy WE, Jenkins MR, Jiang SH, Kaplan W, Leslie S, Llamas B, Mann GJ, McMorran BJ, McWhirter RE, Meldrum CJ, Nagaraj SH, Newman SJ, Nunn JS, Ormond-Parker L, Orr NJ, Paliwal D, Patel HR, Pearson G, Pratt GR, Rambaldini B, Russell LW, Savarirayan R, Silcocks M, Skinner JC, Souilimi Y, Vinuesa CG, The National Centre for Indigenous Genomics; Baynam G. Clinical and population genomic data for Aboriginal and Torres Strait Islander peoples is crucial for equitable provision of expanded carrier screening in Australia Am J Hum Gen 2020 107(2); 175-182

Puri P, Walter GD, Fadia M, Koina M, Gibson KA, Jiang SH The impact of reclassification of C3 predominant glomerulopathies on diagnostic accuracy, outcome and prognosis in patients with C3 glomerulonephritis. BMC Neph 2020 21, 265 (2020).

Jiang SH, Stanley M, Vinuesa CG Rare genetic variants in systemic autoimmunity Immunol Cell Biol 2020 June 22

McKeon KP, Jiang SH Treatment of systemic lupus erythematosus Aus Presc 2020 June 2

Cameron GJM, Cautivo KM, Jiang SH, et. al., Starkey MR. Group 2 Innate Lymphoid Cells Are Redundant in Experimental Renal Ischemia-Reperfusion Injury. Front Immunol. 2019 Apr 16;10:826

Cameron GJM, Jiang SH, Loering S, Deshpande AV, Hansbro PM, Starkey MR. Emerging therapeutic potential of group 2 innate lymphoid cells in acute kidney injury. J Pathol. 2019 May;248(1):9-15.

Jiang SH, Kennard AL, Walters GD. Recurrent glomerulonephritis following renal transplantation and impact on graft survival. BMC Neprol 2018 Dec 3;19(1):344.

Kennard AL, Jiang SH, Walters GD. Increased glomerulonephritis recurrence after living related donation. BMC Nephrology 17; 18(1):25 (2017)

Jiang SH, Shen N, Vinuesa CG. Posttranscriptional T cell gene regulation to limit Tfh cells and autoimmunity. Current Opinion in Immunology, 37:21-7 (2015)

Ellyard, J. E., JerjenR., MartinJ.L., LeeA., FieldM.A., JiangSH., CappelloJ., NaumannS.K., Andrews T.D., ScottH.S., Casarotto M.G., Goodnow C.C., Chaitow J., PascualV., Hertzog P., Alexander S.I., CookM.C., Vinuesa C.G.. Identification of a Pathogenic Variant in TREX1 in Early-Onset Cerebral Systemic Lupus Erythematosus by Whole-Exome Sequencing. Arthritis and Rheumatology, 66(12)3382-3386 (2014)